Immune checkpoint inhibitors, including antibodies against cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), have shown promise in cancer types such as melanoma, NSCLC, and head and neck cancers (76–79). This evidence concerns the gene PDCD1 and head and neck cancer.